Rating Change
Morgan Stanley reiterated its Overweight rating on Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) on October 13, 2026.
reiterateNASDAQ:MIRM
Morgan Stanley Reiterates Overweight Rating on Mirum Pharmaceuticals, Inc. (MIRM)
Morgan Stanley reiterated its Overweight rating on Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) on October 13, 2026.
At publication ·
What changed
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) · reiterate
- Firm
- Morgan Stanley
- Rating
- Overweight to Overweight
- Price at event
- $80.57
- Market capitalization
- $3.2B
At a glance
Key takeaways
- Morgan Stanley reiterated an Overweight rating on Mirum Pharmaceuticals (MIRM) on October 13, 2026, with the stock trading at $80.57 and a market capitalization of $3.2 billion.
Market Context
Mirum Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $80.57 with a market capitalization of $3.2B.
Analyst coverage from Morgan Stanley provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Mirum Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Mirum Pharmaceuticals, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 13, 2026 | Morgan Stanley | Overweight | N/A |
| Oct 12, 2026 | Citigroup | Buy | N/A |
| Oct 12, 2026 | HC Wainwright & Co. | Buy | N/A |
| Oct 08, 2026 | RBC Capital | Outperform | N/A |
| Sep 29, 2026 | Citigroup | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View MIRM Stock Page
Frequently Asked Questions
What does the Overweight rating mean for MIRM?
A rating of Overweight from Morgan Stanley reflects the analyst's outlook on Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MIRM forecast page.